$MRNA, $ALNY, $BGNE, $LEGN, $RPRX, $ROIV fell by 5-8% over the week.
Over the past week, the stock market has continued to decline. Leading the decline are biotechnology company stocks, which have fallen by 5-8%. You can receive signals for these company stocks by subscribing to our robots: Swing-trader-Downtrend-Protection-v-2-TA.
Notable Companies
Some of the most prominent companies in the Biotechnology industry include:
Regeneron Pharmaceuticals (NASDAQ: REGN)
Moderna (NASDAQ: MRNA)
Incyte Corp (NASDAQ: INCY)
Sarepta Therapeutics (NASDAQ: SRPT)
Exelixis (NASDAQ: EXEL)
Arrowhead Pharmaceuticals (NASDAQ: ARWR)
BioCryst Pharmaceuticals (NASDAQ: BCRX)
Adaptive Biotechnologies Corp (NASDAQ: ADPT)
Novavax (NASDAQ: NVAX)
Sorrento Therapeutics (OTC: SRNEQ)
Industry Description
Biotechnology is a diverse field that involves genetic and protein engineering to develop medications and therapies for the treatment and prevention of various medical conditions. Additionally, the industry plays a crucial role in producing essential components for diagnostic purposes. It's a multi-billion-dollar industry with a strong focus on research and development to innovate cutting-edge healthcare solutions.
Discoveries in the biotechnology sector have the potential for substantial growth. However, these breakthroughs must undergo rigorous regulatory approval processes, often by the U.S. Food and Drug Administration (FDA), before they can be introduced to the market. Some well-known companies in this industry include Amgen Inc., Gilead Sciences, Inc., and Celgene Corporation.
Market Capitalization
The average market capitalization within the Biotechnology industry is approximately $2.2 billion. Companies in this sector exhibit a wide range of market capitalization, spanning from $402 million to $410.2 billion. Notably, NVO holds the highest valuation in this group at $410.2 billion, while the lowest valued company is PNEXF at $402 million.
High and Low Price Notable News
Price fluctuations in the Biotechnology industry are quite dynamic. The average weekly price movement across all stocks in this sector was -3.83%. Over a monthly period, the average price growth was more positive at 22.16%, and for a quarter, it further increased to 34.16%. Among individual stocks, RNAZ experienced remarkable price growth at 335.08%, while SEEL faced a significant decline of -80.84%.
Some recent price highlights include:
On 9/6/23 at 7:51 AM, Moderna (MRNA, $109.36) experienced a weekly decline of -5.72%, potentially indicating a trend reversal.
On 8/25/23 at 7:08 AM, Moderna (MRNA, $112.65) showed a substantial weekly gain of +6.03%, suggesting a potential continuation of an uptrend.
On 8/18/23 at 11:29 AM, Moderna (MRNA, $106.24) recorded a significant weekly gain of +5.94%.
Volume
The trading volume in the Biotechnology Industry is subject to fluctuations. On average, there was a weekly volume growth of 62.71% across all stocks in the industry. Over a month, the average volume growth was 135.64%, and for a quarter, it was 125.83%.
Some notable volume events include:
On 9/16/23 at 7:44 AM, the volume for Roivant Sciences stock surged for one day, resulting in an extraordinary daily growth of 315% compared to the 65-Day Volume Moving Average.
On 6/21/23 at 2:33 PM, Royalty Pharma's stock witnessed a consistent increase in volume for five consecutive days, with an average daily gain of 104%.
Fundamental Analysis Ratings
Fundamental analysis ratings help assess the overall health and performance of companies in the industry. These ratings are on a scale from 1 (best) to 100 (worst) and are as follows:
Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -24 (on a scale of -100 to +100)
MRNA sees MACD Histogram crosses below signal line on September 19, 2023. This is a bearish signal, with an 85% chance of a downward move.
ALNY: The 10-day Moving Average crossed above the 50-day moving average on September 01, 2023, suggesting a 78% chance of an upward trend continuation.
BGNE: Broke above its upper Bollinger Band on August 29, 2023, indicating a 90% chance of a subsequent drop.
LEGN moved below its 50-day Moving Average on September 05, 2023, signaling a 90% chance of a continued downward trend.
RPRX: The Aroon Indicator entered a downward trend on September 15, 2023, with a 73% chance of a stock decline.
ROIV: The 10-day RSI Indicator moved out of overbought territory on September 11, 2023, implying a 78% chance of a downward trend.
MRNA in -7.22% downward trend, declining for three consecutive days on May 15, 2025
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MRNA declined for three days, in of 334 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where MRNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 20, 2025. You may want to consider a long position or call options on MRNA as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on May 19, 2025. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.035) is normal, around the industry mean (16.282). P/E Ratio (0.000) is within average values for comparable stocks, (59.596). MRNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (3.303) is also within normal values, averaging (269.262).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MRNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).
Industry description
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Market Cap
The average market capitalization across the Biotechnology Industry is 2.22B. The market cap for tickers in the group ranges from 151 to 303.58B. NONOF holds the highest valuation in this group at 303.58B. The lowest valued company is MYMX at 151.
High and low price notable news
The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was -5%. SPRO experienced the highest price growth at 259%, while REVB experienced the biggest fall at -65%.
Volume
The average weekly volume growth across all stocks in the Biotechnology Industry was -18%. For the same stocks of the Industry, the average monthly volume growth was 51% and the average quarterly volume growth was 126%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Paper wallets are extremely useful tools – beyond being one of the most popular and secure cold storage methods, they make it simple to transfer coins between owners.You can access the funds on your paper wallet by “sweeping” (or importing) them to either a live wallet (like Trezor or Exodus) or an exchange service (like Coinbase).
Most services allow you to import them directly from your wallet’s private key, but there are two key exceptions.
Learn the 27 essential intraday trading rules that every manual trader should master—and discover how Tickeron’s AI platform applies them automatically for consistent, emotion-free execution and smarter, real-time decision-making.
A $2 trillion sell-off has investors asking: is 2025 the next dot-com crash or a replay of the 2008 recession? This deep dive compares both scenarios, outlines warning signs, and reveals how AI-powered trading strategies can help navigate rising volatility.
New to trading? Discover 21 powerful lessons every beginner must learn—and see how Tickeron’s AI Double Agent strategies apply them in real time. From mastering risk to managing emotions, this guide helps you trade smarter, safer, and more confidently.
From the railroads of the 1920s to the AI giants of 2025, market history shows that extreme concentration often precedes massive bubbles and crashes. This article explores five key turning points and how Tickeron’s AI helps traders navigate today’s bubble-prone landscape.
U.S. tariff tensions rocked markets this week, sending tech stocks into retreat and safe-haven assets like gold and the yen soaring. As investors brace for major earnings and global policy shifts, volatility remains high across equities, currencies, and commodities.
Tesla’s Q1 2025 earnings could surprise investors as the EV giant looks to rebound from last quarter’s miss. With lowered expectations and increased volatility, Tickeron’s AI-powered strategy helps traders navigate both upside potential and downside risk.
Gold is on a historic run—up 29% YTD with record-breaking inflows and growing macro tailwinds. Discover why smart investors are eyeing gold, silver, and miners for opportunity, and how AI trading tools are unlocking new ways to profit from the 2025 gold rush.
Tickeron launches its innovative Double Agent Trading Bot, combining long NVDA trades with hedged NVDS positions. Using AI-driven pattern trading and real-time risk management, the bot achieves a 75% success rate, revolutionizing automated trading strategies.
Tickeron’s AI trading bots are setting new standards in finance, achieving up to 86.6% win rates across leveraged and sector ETFs. Powered by advanced Financial Learning Models (FLMs), Tickeron’s AI delivers precision, adaptability, and real-time trading success.
Wall Street expects strong profit growth from the Magnificent Seven tech giants in 2025. Discover how to trade Apple, Microsoft, Amazon, Nvidia, Tesla, Meta, and Alphabet using AI-powered Double Agent strategies and smart hedging with inverse ETFs like QID.
On May 2, 2025, a diverse group of companies across energy, financial services, basic materials, consumer discretionary, and healthcare will release their Q1 2025 earnings.
In April 2025, five tech giants—NVIDIA, Tesla, Meta, Palantir, and Amazon—each surged over 40%, driven by AI breakthroughs, strong earnings, and market momentum. Discover what fueled the rally and how Tickeron’s AI trading bots helped investors outperform even these star stocks.
Markets ended April with mixed signals—gold slid on trade optimism, Big Tech lifted the Nasdaq, and Bitcoin steadied near $94K. With U.S. GDP contracting and job growth beating forecasts, investors brace for more volatility amid tariffs and central bank moves.
In a turbulent market, Tickeron's AI-powered Double Agent Bot is outperforming traditional strategies. Leveraging real-time intraday signals and inverse ETFs, the bot posted a +9.77% quarterly gain while the S&P 500 dropped 9.28%. Here's how AI is reshaping trading.
As Warren Buffett announces his retirement, investors turn to his trusted Buffett Indicator—a ratio of market cap to GDP—as a key gauge of market valuation.
Markets move in repeating cycles—Accumulation, Uptrend, Distribution, and Downtrend. Learn how to recognize each phase and deploy Tickeron’s AI-powered Double Agent strategy to adapt, protect capital, and profit in any market condition.
Discover how confirmation trading techniques—like moving average crossovers and volume-backed breakouts—can improve accuracy and reduce false signals. Learn how Tickeron’s AI automates these strategies for smarter, faster, and more disciplined trading.
Hedge funds are ramping up bearish bets on small-cap stocks, with Russell 2000 short interest hitting new highs. As macro headwinds mount and technical support teeters, Tickeron’s AI Double Agents step in to navigate the looming sell-off with precision.
SPY’s Momentum Indicator turned bullish on April 25, 2025, signaling a potential trend shift with a 90% historical success rate. This article explores how economic scarcity, technical signals, and AI-driven tools like Tickeron’s A.I.dvisor shape investor decisions in volatile markets.